Literature DB >> 19389858

The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride.

Joachim Geyer1, Olga Gavrilova, Ernst Petzinger.   

Abstract

The aim of the present study was to characterize the role of the drug-efflux transporter P-glycoprotein (P-gp) for the disposition of trospium chloride, a widely used anticholinergic drug for the treatment of overactive bladder. P-gp-deficient mdr1a,b(-/-) knockout mice were given either 1 mg/kg trospium chloride orally or 1 mg/kg intravenously to analyze brain penetration, intestinal secretion, and hepatobiliary excretion of the drug. The concentrations of trospium chloride in the brain were up to 7 times higher in the mdr1a,b(-/-) knockout mice compared with wild-type mice (p < 0.05), making P-gp a limiting factor for the blood-brain barrier penetration of this drug. Moreover, the residence time of the drug in the central nervous system was significantly prolonged in mdr1a,b(-/-) knockout mice. Apart from the blood-brain barrier, P-gp also had significant effects on the overall pharmacokinetics of trospium chloride. In the mdr1a,b(-/-) knockout mice, hepatobiliary excretion and intestinal secretion were significantly reduced compared with the wild-type mice. Our study indicates that the multidrug resistance transporter P-gp is a major determinant for the distribution of trospium chloride in the body and highly restricts its entry into the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389858     DOI: 10.1124/dmd.109.027144

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.

Authors:  Peter K Sand; Eric S Rovner; Jonathan H Watanabe; Michael G Oefelein
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.

Authors:  Michael G Oefelein
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

Review 3.  Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.

Authors:  Scott C McFerren; Alex Gomelsky
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

Review 4.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 5.  Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.

Authors:  Dustin Pagoria; R Corey O'Connor; Michael L Guralnick
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

6.  Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.

Authors:  Rujin Ju; Joanne Garrett; Jennifer M Wu
Journal:  Int Urogynecol J       Date:  2013-10-25       Impact factor: 2.894

7.  Oxybutynin and trospium are substrates of the human organic cation transporters.

Authors:  Birger Wenge; Joachim Geyer; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-07       Impact factor: 3.000

Review 8.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

9.  A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

Authors:  Ernesto Callegari; Bimal Malhotra; Peter J Bungay; Rob Webster; Katherine S Fenner; Sarah Kempshall; Jennifer L LaPerle; Martin C Michel; Gary G Kay
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

10.  Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.

Authors:  Peter K Sand; Roger R Dmochowski; Norman R Zinner; David R Staskin; Rodney A Appell
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.